Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PyRFTL: an open source Python tool for custom tube lens generation from off-the-shelf optics.

Optics letters·2025

Same author

Comparison of envelope detection techniques in coherence scanning interferometry.

Applied optics·2016

Same author

BioAssay Research Database (BARD): chemical biology and probe-development enabled by structured metadata and result types.

Nucleic acids research·2014

Same author

Local frequency and envelope estimation by Teager-Kaiser energy operators in white-light scanning interferometry.

Optics express·2014

Same author

Definitions of sleeplessness in children with attention-deficit hyperactivity disorder (ADHD): implications for mothers' mental state, daytime sleepiness and sleep-related cognitions.

Child: care, health and development·2014

Same author

Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial.

BMJ (Clinical research ed.)·2012

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Parkinson's disease: a pharmacological update.

S Chater, P Montgomery

Canadian Family Physician Medecin De Famille Canadien

|January 29, 2011

Summary

Parkinsonism treatment focuses on dopamine depletion. While L-dopa is effective, its use is limited by complications; other drugs like anticholinergics and amantadine help early symptoms, with tailored approaches improving motor function.

Area of Science:

Neurology
Pharmacology

Background:

Parkinsonism is characterized by dopamine depletion.
Early symptomatic treatment includes anticholinergics and amantadine.
Levodopa (L-dopa) is highly effective but associated with late-onset dyskinesias.

Purpose of the Study:

To review current pharmacological treatments for Parkinsonism.
To discuss the efficacy and limitations of various drugs.
To emphasize individualized treatment strategies focusing on motor function.

Main Methods:

Review of existing literature on Parkinsonism pharmacotherapy.
Analysis of drug efficacy, side effects, and patient-specific considerations.
Discussion of current treatment paradigms and future directions.

More Related Videos

Phenotypic Profiling of MPTP-Induced Parkinsonian-like Behavioral Phenotypes in Zebrafish Larvae Based on Behavioral Experiment

Phenotypic Profiling of MPTP-Induced Parkinsonian-like Behavioral Phenotypes in Zebrafish Larvae Based on Behavioral Experiment

Published on: May 15, 2026

Related Experiment Videos

Last Updated: Jun 4, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Phenotypic Profiling of MPTP-Induced Parkinsonian-like Behavioral Phenotypes in Zebrafish Larvae Based on Behavioral Experiment

Phenotypic Profiling of MPTP-Induced Parkinsonian-like Behavioral Phenotypes in Zebrafish Larvae Based on Behavioral Experiment

Published on: May 15, 2026

Main Results:

Anticholinergics and amantadine are beneficial in early stages.
Levodopa remains the most effective drug but has significant long-term complications.
Dopamine agonists like bromocriptine show relative effectiveness, but optimal timing is unclear.
Beta-blockers may help manage tremor.
Dyskinesias and neuropsychiatric issues are key challenges limiting drug use.

Conclusions:

Treatment for Parkinsonism requires patient-specific tailoring.
Focus should be on optimizing functional motor ability.
Managing drug-induced complications like dyskinesias is crucial.
Several new drugs are under investigation for Parkinsonism.